Moderna's Q3 Spikevax Sales Exceed Expectations Despite RSV Setback and Market Challenges

In the third quarter, Moderna's Spikevax COVID-19 vaccine experienced a remarkable surge in sales, generating $1.8 billion in revenue, which exceeded analysts' expectations significantly[1][3]. The revenue generated from Spikevax was primarily driven by strong sales in the United States, which alone contributed $1.2 billion[1]. This impressive performance can be attributed to the early approval of the adapted vaccine, which allowed Moderna to capitalize on market opportunities faster than some competitors[3]. Despite this success, Moderna has maintained its annual revenue guidance between $3 billion and $3.5 billion, reflecting cautious optimism amid a contracting market[2].